Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy

  • Querol, Luis|||0000-0002-4289-8264
  • Siles, Ana M..
  • Alba-Rovira, Roser|||0000-0003-3308-5787
  • Jáuregui, Agustín
  • Devaux, Jérôme|||0000-0001-6383-4334
  • Faivre-Sarrailh, Catherine
  • Araque, Josefa
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Nogales, Gisela|||0000-0002-7414-212X
  • Navas Madroñal, Miquel|||0000-0003-2984-1471
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. We developed a screening protocol to uncover novel reactivities in CIDP. Sixty-five CIDP patients and 28 controls were included in our study. Three patients (4.6%) had antibodies against neurofascin 155, four (6.2%) against contactin-1 and one (1.5%) against the contactin-1/contactin-associated protein-1 complex. Eleven (18.6%) patients showed anti-ganglioside antibodies, and one (1.6%) antibodies against peripheral myelin protein 2. No antibodies against myelin protein zero, contactin-2/contactin-associated protein-2 complex, neuronal cell adhesion molecule, gliomedin or the voltage-gated sodium channel were detected. In IgG experiments, three patients (5.3%) showed a weak reactivity against motor neurons; 14 (24.6%) reacted against DRG neurons, four of them strongly (7.0%), and seven (12.3%) reacted against Schwann cells, three of them strongly (5.3%). In IgM experiments, six patients (10.7%) reacted against DRG neurons, while three (5.4%) reacted against Schwann cells. However, results were not statistically significant when compared to controls. Immunoprecipitation experiments identified CD9 and L1CAM as potential antigens, but reactivity could not be confirmed with cell-based assays. In summary, we describe a diverse autoantibody repertoire in CIDP patients, reinforcing the hypothesis of CIDP's pathophysiological heterogeneity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo

  • Manso, Constance
  • Querol, Luis|||0000-0002-4289-8264
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Poncelet, Mallory
  • Mekaouche, Mourad
  • Vallat, Jean-Michel
  • Illa, Isabel|||0000-0002-2186-2684
  • Devaux, Jérôme|||0000-0001-6383-4334
Neurofascin-155 (Nfasc155) is an essential glial cell adhesion molecule expressed in paranodal septate-like junctions of peripheral and central myelinated axons. The genetic deletion of Nfasc155 results in the loss of septate-like junctions and in conduction slowing. In humans, IgG4 antibodies against Nfasc155 are implicated in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). These antibodies are associated with an aggressive onset, a refractoriness to intravenous immunoglobulin, and tremor of possible cerebellar origin. Here, we examined the pathogenic effects of patient-derived anti-Nfasc155 IgG4. These antibodies did not inhibit the ability of Nfasc155 to complex with its axonal partners contactin-1 and CASPR1 or induce target internalization. Passive transfer experiments revealed that IgG4 antibodies targeted Nfasc155 on Schwann cell surfaces, and diminished Nfasc155 protein levels and prevented paranodal complex formation in neonatal animals. In adult animals, chronic intrathecal infusions of antibodies also induced the loss of Nfasc155 and of paranodal specialization and resulted in conduction alterations in motor nerves. These results indicate that anti-Nfasc155 IgG4 antibodies perturb conduction in the absence of demyelination, validating the existence of paranodopathy. These results also shed light on the mechanisms regulating protein insertion at paranodes.